Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.
Soligenix, Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company headquartered in Princeton, New Jersey. The company is dedicated to developing and commercializing products that address unmet medical needs, particularly in the areas of inflammation, oncology, and biodefense. Soligenix operates through two business segments: Specialized BioTherapeutics and Public Health Solutions.
Under the Specialized BioTherapeutics segment, Soligenix focuses on rare disease treatments. Key projects include HyBryte™ (SGX301), a novel photodynamic therapy using synthetic hypericin for cutaneous T-cell lymphoma (CTCL). HyBryte™ has shown promising results in Phase 3 clinical trials and is on track for regulatory approvals in the United States and Europe. Other development programs include SGX302 for psoriasis, SGX942 for oral mucositis in head and neck cancer, and SGX945 for Behçet's disease.
The Public Health Solutions segment emphasizes vaccine development and biodefense. Notable projects include RiVax®, a ricin toxin vaccine candidate, and thermostable vaccine candidates for filoviruses such as Marburg and Ebola. These vaccines are developed using the company's proprietary heat stabilization platform technology, ThermoVax®. Soligenix has also been active in developing CiVax™, a vaccine candidate for COVID-19.
Recent achievements include additional patents for their trivalent filovirus vaccine platform and positive clinical trial results for HyBryte™. Financially, the company reported a net loss for the quarter ended March 31, 2024, but successfully raised $4.75 million through a public offering. Soligenix has also secured significant non-dilutive government funding to support its various development programs.
Partnerships with esteemed institutions like the University of Hawaiʽi at Mānoa and funding from organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) further bolster Soligenix's research and development efforts. With a robust pipeline and strategic collaborations, Soligenix aims to deliver significant long-term value to its shareholders and address critical healthcare needs globally.
SG Blocks is leading the seed round investment in Moliving, a luxury nomadic hospitality solution, to enhance modular living and hospitality. The funds will support the construction of 60 units for Moliving's flagship hotel in Hudson Valley, with potential for 400 additional units through five planned locations in 2023. This collaboration highlights the synergy between SG Blocks and Moliving, as both aim to meet market demands sustainably. The flagship hotel, Moliving at Hurley House, is set to open in Summer 2022.
Soligenix, Inc. (Nasdaq: SNGX) has announced that Jonathan Guarino, CFO, will present at the Q1 Virtual Investor Summit on March 8, 2022, at 1:15 PM EST. The summit runs from March 8-9 and features one-on-one meetings and company presentations. Attendees can access the presentation through the event platform. Soligenix focuses on treating rare diseases, with products like HyBryte™ for cutaneous T-cell lymphoma and vaccine candidates for various infectious diseases.
Soligenix, a late-stage biopharmaceutical company focused on rare diseases, will present at the BIO CEO & Investor Conference from February 14-17, 2022. The presentation, available on-demand from February 11, will be led by CEO Christopher J. Schaber, PhD. Attendees can also schedule one-on-one meetings with management during the conference. Soligenix is advancing potential treatments like HyBryte™ for cutaneous T-cell lymphoma and RiVax® for ricin toxin exposure. For more details, visit the conference website.
Soligenix (SNGX) provided an update on its strategic plans and development pipeline in a letter from CEO Dr. Christopher J. Schaber. Key upcoming milestones include submitting an NDA for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) and initiating a Phase 2 trial for SGX302 in psoriasis. HyBryte™ shows potential peak U.S. sales exceeding $90 million, with a global psoriasis market opportunity over $1 billion. Additionally, ongoing development of vaccines and the significance of a $20 million partnership with Pontifax were highlighted, ensuring sufficient capital into 2023.
Soligenix (Nasdaq: SNGX), a late-stage biopharmaceutical company, announced its participation in two upcoming virtual investor conferences. The H.C. Wainwright BioConnect Conference will take place from January 10-13, 2022, with an on-demand presentation available starting January 10 at 7 AM ET. The Biotech Showcase will be held from January 10-12 and 17-19, 2022, with presentations for registered attendees commencing on January 10. Soligenix's management will also conduct one-on-one meetings throughout both conferences.
Soligenix, Inc. (Nasdaq: SNGX) announced that dusquetide shows significant efficacy in reducing tumor size in nonclinical models, reinforcing previous studies. It was effective both as a standalone therapy and in combination with radiation and chemotherapy for the MCF-7 breast cancer cell line. Dusquetide has also shown positive results in reducing severe oral mucositis, leading to enhanced survival rates. The company is exploring further product opportunities in oncology, motivated by strong Phase 2 and 3 study data. Dusquetide holds Fast Track Designation for treating oral mucositis, with a robust intellectual property portfolio backing its development.
Soligenix, Inc. (SNGX) announced successful 100% protection of non-human primates against lethal Sudan ebolavirus using a bivalent, thermostabilized vaccine. This achievement highlights the potential of their vaccine platform, crucial for pandemic preparedness. The vaccine maintains full potency and can be reconstituted with just water, enabling storage at ambient temperatures. The ongoing collaboration with the University of Hawaiʻi aims to accelerate vaccine development for various filoviruses, including Sudan and Marburg, which currently lack effective vaccines.
Soligenix (SNGX) announced its Q3 2021 financial results, reporting revenues of $0.2 million compared to $0.6 million in Q3 2020. The net loss increased to $3.6 million or ($0.09) per share, driven by reduced revenues and higher R&D costs primarily for HyBryte™. The Company holds approximately $29 million in cash and is preparing for an NDA filing for HyBryte™, which has received orphan drug designation for T-cell lymphoma. Additionally, Soligenix plans to expand synthetic hypericin development into psoriasis with a Phase 2a trial set for mid-2022.
Soligenix, Inc. (Nasdaq: SNGX) announced it received a Pediatric Investigation Plan (PIP) waiver from the Medicines and Healthcare products Regulatory Agency (MHRA) for its treatment, HyBryte™ (SGX301), for cutaneous T-cell lymphoma (CTCL). This waiver facilitates regulatory processes in the UK, avoiding costly pediatric clinical studies. Earlier, the EMA granted a similar waiver. The Phase 3 FLASH trial demonstrated significant efficacy, with 40% of patients responding positively to HyBryte™. Soligenix emphasizes the safety of HyBryte™ compared to existing therapies, marking a crucial step in advancing its clinical development.
Soligenix, Inc. (Nasdaq: SNGX) announced a new publication confirming that its RiVax® vaccine offers enduring protection against ricin toxin for at least 12 months post-vaccination. The findings were published in mSphere and highlight previous efficacy trials in animals. The vaccine's thermostability could facilitate stockpiling for emergency use. Soligenix intends to pursue FDA approval under the 'Animal Rule,' given the ethical concerns of human trials. The development is backed by over $40 million in non-dilutive funding. RiVax® has received Orphan Drug and Fast Track designations from the FDA.
FAQ
What is the current stock price of Soligenix (SNGX)?
What is the market cap of Soligenix (SNGX)?
What does Soligenix, Inc. specialize in?
What are the key projects under Soligenix's Specialized BioTherapeutics segment?
What is ThermoVax®?
What achievements has Soligenix recently made?
Who are some of Soligenix's key partners?
What financial milestones has Soligenix achieved?
What is HyBryte™?
What is CiVax™?
What is RiVax®?
What are Soligenix's key areas of focus in vaccine development?
